Here, we investigated the structural requirements of compounds that selectively inhibit PSEN1–γ-secretase complexes versus PSEN2–γ-secretases as those were shown to provide a therapeutic window in preclinical models of AD and T-ALL (7, 19, 21). The gene discussed is PSEN1; the disease is acute lymphoblastic leukemia.